Werewolf Therapeutics (HOWL) Expected to Announce Earnings on Tuesday

Werewolf Therapeutics (NASDAQ:HOWL) is anticipated to announce its Q3 2026 results before the market opens on Tuesday, November 3rd. Analysts expect Werewolf Therapeutics to post earnings of ($0.22) per share and revenue of $18.31 million for the quarter. Interested persons can check the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Friday, November 6, 2026 at 8:30 AM ET.

Werewolf Therapeutics (NASDAQ:HOWL) last released its quarterly earnings data on Friday, July 31st. The company reported $0.08 EPS for the quarter, topping the consensus estimate of ($0.28) by $0.36. The firm had revenue of $21.00 million for the quarter, compared to analysts’ expectations of $21.00 million. On average, analysts expect Werewolf Therapeutics to post ($0.89) EPS for the current fiscal year and ($0.59) EPS for the next fiscal year.

Werewolf Therapeutics Stock Up 0.1%

Shares of NASDAQ HOWL opened at $0.98 on Tuesday. The business has a fifty day simple moving average of $0.92 and a two-hundred day simple moving average of $0.67. The firm has a market cap of $47.66 million, a PE ratio of -1.29 and a beta of 0.51. Werewolf Therapeutics has a twelve month low of $0.27 and a twelve month high of $1.83.

Analysts Set New Price Targets

HOWL has been the topic of a number of recent research reports. Wall Street Zen raised Werewolf Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 22nd. Zacks Research raised shares of Werewolf Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 5th. Finally, Weiss Ratings upgraded shares of Werewolf Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, September 10th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Werewolf Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $4.00.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc is a clinical-stage biotechnology company focused on developing cancer treatments that stimulate the immune system. The company’s approach is designed to activate immune responses within the tumor microenvironment while limiting exposure to healthy tissues.

Werewolf’s technology platform, known as INDUKINE, uses conditionally activated cytokines. These therapeutic proteins are intended to remain inactive in the bloodstream and become activated primarily in tumors, where they may help recruit and enhance immune cells to attack cancer.